Cure8 research brief
Researchers are exploring plant-based formulas for inflammation beyond the gut. If the SGD effects translate to humans, it could point to new ways to prevent or treat liver injury that can accompany active UC by targeting macrophage metabolism.
Researchers studying IBD complications, liver injury in IBD, macrophage immunometabolism, and investigators of botanical or ethnopharmacological therapies; clinicians interested in mechanisms of extraintestinal manifestations may find the biology of interest.
This abstract reports a preclinical mouse study testing a traditional Chinese herbal formula, Shaoyao Gancao Decoction (SGD), in a dextran-sulfate-sodium model of ulcerative colitis with secondary liver injury.
The authors measured colon and liver histology, serum ALT/AST, RNA-sequencing, metabolomics, molecular docking, and macrophage polarization experiments.
SGD was associated with reduced colon and liver damage, lower ALT/AST, shifts in hepatic glycometabolism-related signaling, increased TCA flux in LPS-stimulated macrophages, and inhibition of M1 macrophage polarization.
The proposed mechanism is blockade of PDK–PDH interaction (preventing PDH phosphorylation); molecular docking identified benzoylpaeoniflorin and glycyrrhizic acid as candidate binding components. The PDH inhibitor attenuated SGD's effect on macrophage polarization in their experiments.
This is an abstract of a preclinical (mouse and cell-based) study reported in Journal of Ethnopharmacology. Findings are mechanistic and exploratory; they do not demonstrate safety or efficacy in people. Molecular docking and metabolomics suggest hypotheses but are not clinical proof.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study describes a new oral-delivery microsphere that improved loading and gut-targeted release of celastrol and showed beneficial effects in a mouse colitis model and on gut microbiota. If translatable, this approach...
Researchers are exploring microbiome-derived molecules as targeted, locally acting therapies for ulcerative colitis that might avoid systemic immunosuppression. EB1010 showed anti-inflammatory activity and...
Fibrosis and stricturing are key problems in Crohn’s disease with limited therapies; this study identifies a microbiota–bile acid–GPBAR1 pathway by which a specific probiotic mix reduced inflammation and fibrosis in...
